UP FRONT MATTERSBrief Review

The Pathophysiology of the Peritoneal Membrane

Olivier Devuyst, Peter J. Margetts and Nicholas Topley
JASN July 2010, 21 (7) 1077-1085; DOI: https://doi.org/10.1681/ASN.2009070694

Abstract

The development of peritoneal dialysis (PD) as a successful therapy has and still depends on experimental models to test and understand critical pieces of pathophysiology. To date, the majority of studies performed in rat and rabbit models derive mechanistic insights primarily on the basis of interventional pharmacologic agents, blocking antibodies, or transient expression systems. Because body size no longer limits the performance of in vivo studies of PD, genetic mouse models are increasingly available to investigate the molecular and pathophysiologic mechanisms of the peritoneal membrane. We illustrate in this review how these investigations are catching up with other areas of biomedical research and provide direct evidence for understanding transport and ultrafiltration, responses to infection, and structural changes including fibrosis and angiogenesis. These studies are relevant to mechanisms responsible not only for the major complications of PD but also for endothelial biology, host defense, inflammation, and tissue repair processes.

Peritoneal dialysis (PD) is a life-sustaining therapy used by >100,000 patients with ESRD worldwide, accounting for approximately 10 to 15% of the dialysis population.1 The major obstacles to successful long-term PD are infection and deleterious functional alterations in the peritoneal membrane after exposure to dialysis solutions; this loss of dialysis capacity is responsible for increased morbidity and mortality. These alterations, involving approximately 50% of all PD patients, include progressive fibrosis, angiogenesis, and vascular degeneration associated with increased solute transport and loss of ultrafiltration (UF).2–4 In a small percentage of cases, a poorly defined but catastrophic fibrogenic response occurs primarily in the visceral peritoneum, leading to the onset of encapsulating peritoneal sclerosis (EPS) with an associated high mortality rate.5,6

In the past two decades, clinical improvements in therapy delivery and prescription have been introduced, including new dialysis solutions, improved connections, automated PD, and tailored antibiotic strategies. Although these advances reduce the incidence of peritonitis, infectious complications remain a problem, as does membrane failure. There is thus a growing need to understand the molecular basis of these membrane-degenerative events and a need to establish suitable experimental models to define better various aspects of the therapy. This includes a better understanding of transport mechanisms across the peritoneal membrane, improved definition of the response of the peritoneum to infection and inflammation, and deciphering the molecular mechanisms that drive peritoneal fibrosis and vascular damage that lead to membrane dysfunction.4 Many of these investigations using either in vivo animal models or in vitro cell-based systems are based on interventional studies with pharmacologic agents, with blocking antibodies, or in transient overexpression systems.7–10 Although these studies provide significant insight into peritoneal pathophysiology, it is widely acknowledged that they are limited in some cases by a lack of pathway specificity, adverse effects, and transient efficacy, so many questions remain to be addressed.11–13 Until recently, the body size of a species was considered a major limiting factor in performing in vivo studies relevant to PD; however, the development of new approaches for in vivo phenotyping14 coupled with molecular biology techniques provides the potential of using genetically modified mice for clinically relevant mechanistic studies addressing various key aspects of PD pathophysiology.15,16 The purpose of this brief review is to illustrate how these studies (primarily in rodent models) provide a more complete understanding of basic mechanisms and pave the way for the development of novel, specifically targeted diagnostic and therapeutic strategies aimed at reducing infection and improving membrane survival and long-term outcomes in patients who are on PD.

Peritoneal Transport, Aquaporins, and UF

Once technical issues were overcome, mouse models were initially used to characterize the general structure of the visceral and parietal peritoneum that is effectively undistinguishable from that described in rats and humans.16,17 Furthermore, the specific distribution of the water channel aquaporin 1 (AQP1) and endothelial nitric oxide synthase (eNOS) in distinct vascular beds have been confirmed, and exposure of mice to standard glucose dialysis solutions yields equilibration curves for urea and glucose, sodium sieving, and a net UF that are remarkably similar to those obtained in rats and humans.16

The capacity for UF across the peritoneal membrane is a major predictor of outcome and mortality in PD patients.18,19 According to the three-pore model, the major transport barrier of the membrane is the capillary endothelium, which contains ultrasmall pores (radius <3Å) that facilitate the osmotic transport of water.20 Computer simulations have predicted these ultrasmall pores account for approximately 50% of the UF and explain the sodium sieving—the marked fall of the dialysate-to-plasma ratio of sodium during the first hour of PD with hypertonic dialysate.21 The identification of AQPs, a family of integral plasma membrane proteins conserved in bacteria, plants, and mammals, provided critical insights in the molecular mechanisms involving water permeation across biological membranes.22 The first member of the AQP family to be identified, AQP1, is abundantly expressed in endothelial cells lining peritoneal capillaries, consistent with the predicted topology of ultrasmall pores (Figure 1).23,24

Figure 1.
Figure 1.

Distribution and role of AQP1 in the peritoneal membrane. (A) Cross-section of the human parietal peritoneum stained for AQP1. AQP1 is detected in the endothelium lining peritoneal capillaries, venules, and small veins. m, mesothelium. Bar = 40 μm). (B) Immunogold electron microscopy on mouse visceral peritoneum unicryl sections shows a very strong signal for AQP1 in the plasma membrane and plasma membrane infoldings of capillary endothelial cells. Bar = 500 nm. (C and D) Effect of AQP1 deletion on the transport of water across the peritoneal membrane. Mice with a targeted deletion of Aqp1 are investigated using a peritoneal equilibration test essentially similar to that performed in patients. The dialysate-to-plasma ratio (D/P) of sodium (C) and the initial UF rates calculated from the first derivate of the best fitting curves for each mouse (D) are determined in Aqp1+/+ mice (purple symbols), Aqp1+/− mice (blue symbols), and Aqp1−/− mice (red symbols) during a 2-hour exchange with hypertonic dialysate. In comparison with Aqp1+/+ mice, mice lacking AQP1 show a complete loss of sodium sieving and significantly lower initial UF rates. Intermediate values of sodium sieving and initial UF rates are observed in Aqp1+/− mice. Adapted from Ni et al.,26 with permission.

This hypothesis has been substantiated by Yang et al.,25 who showed that osmotically driven water transport across the peritoneum (estimated by a tracer dilution) was decreased in mice lacking AQP1. Ni et al.26 used an infusion model to demonstrate that, in comparison with control littermates, AQP1 knockout mice lack sodium sieving and have a major decrease in UF, despite unchanged osmotic gradient (Figure 1). The use of AQP1-deficient mice thus validates the three-pore model and provides direct evidence for the role of water channels in PD. Increasing the expression (or function) of AQP1 in the peritoneum, with, for example, corticosteroid treatment, might thus be a potential approach to treating UF failure in PD patients.27

Acute Peritonitis: Role of NOS Isoforms

Acute peritonitis is characterized by an increased endothelial exchange area, with increased transport of small solutes and glucose, loss of proteins into the dialysate, and dissipation of the osmotic gradient, leading to UF failure.28,29 Vasoactive substances released during the inflammation reaction, particularly NO, play a role in these changes.30 Indeed, inhibition of NOS with NG-nitro-l-arginine methyl ester improve UF and reverse permeability changes in rat and mouse models of acute peritonitis.8,31 The three NOS isoforms—neuronal NOS (nNOS, NOS1), inducible NOS (iNOS, NOS2), and eNOS (NOS3)—are differentially expressed in the peritoneal membrane.32

The neuronal and endothelial isozymes are constitutive isoforms, their activity being controlled by intracellular Ca2+ levels, whereas iNOS is quiescent until its transcription is activated by LPS and/or cytokines.33 The use of peritonitis models in mice lacking specific NOS isoforms demonstrates the importance of NO for structural and transport-related alterations induced by acute peritoneal infection or inflammation. The deletion of eNOS, which has no effect on peritoneal structure or transport at baseline, significantly attenuates the vascular proliferation and the inflammatory infiltrate (in a catheter-induced model of Gram-positive bacterial peritonitis), resulting in improved UF and reduced protein loss in the dialysate (Figure 2).15 Further investigations using a model of LPS-induced peritonitis in mice deficient for each NOS isoform confirm the specific role of eNOS in mediating increased solute transport and loss of UF associated with peritonitis, whereas neuronal NOS and iNOS have no effect.34 In contrast, iNOS null mice show more severe inflammatory changes and a trend toward increased mortality after LPS treatment. These data identify specific roles for NOS isoforms in the peritoneal membrane and suggest selective eNOS inhibition may improve peritoneal transport parameters and prevent vascular changes during acute peritonitis.

Figure 2.
Figure 2.

The role of eNOS in transport and structural changes induced by acute peritonitis is investigated using a 5-day catheter-induced peritonitis model in wild-type mice (eNOS WT-p) or littermates lacking eNOS (eNOS KO-p). The lack of eNOS is reflected by a significant reduction in the vascular proliferation (A, staining with the endothelial marker CD31; C, morphometry analyses) and a marked reduction in the transport of small solutes (B, dialysate-to-plasma ratio (D/P) for urea during a 2-hour dwell, n = 6 mice in each group; C, area under curve [AUC]) and in the loss of protein in the dialysate (C). Data compiled from Ni et al.15.

Regulation of Peritoneal Inflammation and Leukocyte Trafficking

Acute peritonitis is well described in PD patients and studied in murine models. It begins with infiltration of leukocytes into the peritoneal membrane, starting with a rapid accumulation (within 12 to 24 hours) of neutrophils, which are progressively cleared and replaced by a population of mononuclear cells, monocytes and/or macrophages, and lymphocytes. This temporal switch in the pattern of leukocyte recruitment plays a critical role in the clearance of infection.35 IL-6 is a key mediator involved in this regulation, because IL-6 also suppresses the accumulation of neutrophils in other inflammatory tissues.36 This IL-6–mediated response depends on the presence of its soluble IL-6 receptor (sIL-6R), which forms a ligand–receptor complex allowing IL-6 signaling in cell types lacking the cognate IL-6R, through the ubiquitously expressed transducing molecule, gp130. Through this mechanism, the sIL-6R/IL-6 complex (so called transsignaling) modulates the expression of specific chemokines and adhesion molecules and regulates the process of apoptosis, thereby influencing leukocyte recruitment (Figure 3).37–40 This control primarily results from chemotactic cytokine production by the mesothelial cells lining the peritoneal cavity.41 These cells contribute to proinflammatory cytokine-driven activation and synthesize large amount of IL-6 during inflammation42; however, they do not express the cognate IL-6R and are thus regulating chemokine synthesis only when exposed to the agonistic sIL-6R/IL-6 complex (Figure 3).38

Figure 3.
Figure 3.

IL-6 and sIL-6R signaling in the regulation of leukocyte trafficking. The regulation of leukocyte trafficking in the peritoneal cavity is mediated by proinflammatory cytokine–driven (IL-1, TNF-α, and IFN-γ) activation of IL-6/sIL-6R transsignaling mediated through control of STAT3 activation that results in differential control of chemokine secretion (that is responsible for mononuclear leukocyte and T cell recruitment) and polymorphonuclear neutrophils (PMN) apoptosis. The scheme is derived from data in murine models of acute inflammation and from measurements in the effluent of patients with episodes of peritonitis.

For gaining insights into the mediators controlling the pattern of leukocyte recruitment during peritoneal inflammation, a mouse model of acute peritoneal inflammation was established by using a controlled dose of cell-free supernatant of Staphylococcus epidermidis, a major cause of PD-associated peritonitis.38 The model recapitulates the pattern of inflammatory events encountered during human PD peritonitis, with early activation of proinflammatory cytokines (TNF-α, IL-1, and IFN-γ) and subsequent changes in chemokine expression and the rapid recruitment of neutrophils and their subsequent replacement by monocytes.38 By combining clinical and in vitro investigations with studies in IL-6 null mice, it is believed that the initial attraction of neutrophils by proinflammatory cytokine-driven expression of CXC chemokine, MIP-1/KC, is followed by the release of sIL-6R shed from neutrophils, facilitating the formation of sIL-6R/IL-6 complexes. In turn, these complexes suppress the release of other CXC chemokines, ensuring clearance of neutrophils, and simultaneously promoting the secretion of the CC chemokines, such as monocyte chemoattractant protein 1 (MCP-1) and RANTES, triggering the recruitment of mononuclear leukocytes.38 Further studies using IFN-γ null mice establish that IFN-γ is also involved in controlling the initial recruitment of neutrophils, by affecting the local activities of IL-6 and IL-1β, but also in the promotion of their apoptosis and clearance.39 Using knock-in mice expressing mutant forms of the IL-6 signal transducer molecule gp130, McLoughlin et al.40 showed that IL-6/sIL-6R signaling also selectively promotes T cell recruitment into the peritoneal membrane through a gp130-dependent, STAT1/3-dependent activation pathway. Taken together, these studies provide useful insight into the actions of IL-6 and its soluble receptor during acute inflammation and suggest that while the transition from innate immunity to acquired immunity facilitates the resolution of inflammation and the clearance of bacterial infection in the peritoneum, dysregulation of this pathway as occurs in chronic inflammation or after repeated infections also contributes to inflammation-induced peritoneal damage. These studies provide clear evidence for therapeutic intervention to reduce inflammation43 and to promote the clearance of bacterial infections (N.T. and S.A. Jones, unpublished data).

Transgenic Mice Used for Cellular Studies

A major interest of transgenic mice is the possibility of harvesting cells to develop primary cultures to investigate the role of specific molecules in a given cell population. This approach has been used to investigate the role of Toll-like receptor 4 (TLR4) in murine peritoneal mesothelial cells (MPMC) exposed to inflammation.44 Kato et al.44 developed primary cell cultures of MPMC derived from either C3H/HeN mice (wild-type; LPS sensitive) or C3H/HeJ mice (that lack the response to LPS). Using this system, they observed the induction of MCP-1 and macrophage inflammatory protein 2 (MIP-2) by MPMC stimulated with lipid A depends on the expression of TLR4. Furthermore, leukocyte recruitment into the peritoneal cavity and the production of MCP-1 and MIP-2 in response to LPS are significantly increased in C3H/HeN mice as compared with C3H/HeJ mice. Thus, TLR4 is directly involved in the production of chemokines by mesothelial cells, suggesting that TLR4-mediated pathways reduce the detrimental consequences of peritoneal inflammation. Recent studies45 also showed that treatment with the soluble form of TLR2 modulates peritoneal inflammation and leukocyte recruitment and does not have a negative impact on bacterial clearance in a peritoneal infection model. These data suggest that therapeutic intervention against inflammation can be achieved without compromising peritoneal host defense.

Fibrosis Pathways, Angiogenesis, and Epithelial-to-Mesenchymal Transition

Studies have demonstrated that peritoneal mesothelial cells undergo epithelial-to-mesenchymal transition (EMT) after exposure to injury46 or associated growth factors (Figure 4) to form fibroblasts.47 Furthermore, EMT of peritoneal mesothelial cells is associated with angiogenic stimuli48 and altered solute transport.49 Angiogenesis and fibrosis seem to be intimately linked through common initiating growth factors and inflammatory cytokines and the EMT process. Understanding the mechanisms of fibrosis and the interaction with angiogenesis is therefore important to developing therapeutic strategies to preserve the peritoneum as a dialysis membrane.

Figure 4.
Figure 4.

Peritoneal mesothelial cells undergo EMT. The peritoneum of mice was stained for the epithelial marker cytokeratin in green and the mesenchymal marker α-smooth muscle actin (α-SMA) in red. (A through C) In animals exposed to TGF-β, cells with epithelial characteristics (teal arrows) are intermingled with cells expressing both epithelial and mesenchymal markers (white arrows) and fully differentiated myofibroblasts (red arrows). (D through F) Unexposed animals reveal a single mesothelial cell layer positive for cytokeratin with no α-SMA expression. Nuclei are counterstained with DAPI (blue). Magnification, ×200.

Epithelial-to-Mesenchymal Transition

EMT is an essential process in embryogenesis,50 is beneficial in normal wound healing,51 but is pathogenic in malignancy52 and fibrosis.53 There is increasing evidence to suggest that treatment to prevent EMT may also ameliorate peritoneal fibrosis and angiogenesis and therefore preserve the peritoneal membrane.54 EMT is a cellular program consisting of a loss of cell–cell and cell–matrix interaction and cell polarity, cytoskeletal rearrangement, and basement membrane degradation with subsequent migration or invasion.55 Recently, biomarkers for EMT have been categorized and include the loss of the epithelial adhesion protein E-cadherin and upregulation of mesenchymal markers such as fibroblast-specific protein 1.56

E-cadherin expression is regulated at multiple levels, including gene expression and both extracellular and intracellular protein cleavage. E-cadherin gene expression is suppressed by a family of regulatory proteins, including zinc finger DNA–binding proteins Snail,57 Slug,58 Twist,59 ZEB1, and ZEB2.60 These proteins are, in turn, regulated by growth factors such as PDGF, TGF-β, and Wnt proteins.60

The complex pathways involved in EMT have been investigated in transgenic mouse models, but these have yet to be studied in the peritoneum to any extent. Smads are key signal transduction proteins involved in TGF-β signaling, and the role of Smad3 in EMT in vivo is somewhat controversial. In the kidney, Smad3 is essential for EMT,61 but EMT is observed in Smad3 knockout mice with local ocular lens overexpression of TGF-β.62 EMT has been studied in mesothelial cell cultures, which reveal mammalian target of rapamycin (mTOR) may have a role in peritoneal EMT, and the mTOR inhibitor, rapamycin, has been shown to maintain E-cadherin expression in the face of TGF-β–induced EMT.63 Likewise, bone morphogenic protein 7 acts as a TGF-β antagonist and in mesothelial cell culture reverses EMT.54

Invasion is essential in the full EMT process. Matrix metalloproteinease 2 (MMP-2) and MMP-9 have been studied extensively, because they are gelatinases with specificity for basement membrane–associated collagen type IV. Aside from this collagenase activity, MMPs have a variety of other effects, including cleavage of growth factor precursors and growth factor–binding proteins64 and altering activity of other receptors and proteinases.65 MMP-2 is specifically implicated in EMT, and inhibition of MMP-2 inhibits EMT in renal tubular cell culture.66 Metalloproteinase inhibitors have been evaluated in a mouse model of peritoneal fibrosis using repeated injections of chlorhexidine gluconate.67 The MMP inhibitor suppresses peritoneal fibrosis and angiogenesis, but the effect on EMT was not evaluated.

Peritoneal Membrane Fibrosis and Angiogenesis

The most consistent change observed in the peritoneal tissues of a patient who is on PD is an increase in the submesothelial thickness associated with peritoneal fibrosis and angiogenesis (Figure 5).3,4 In some rare cases, peritoneal fibrosis manifests as an aggressive encapsulation of the bowels (EPS) with significant associated morbidity and mortality.68 Fibrosis and angiogenesis seem to occur together in peritoneal tissues,69 and interventions that reduce angiogenesis also reduce fibrosis.70

Figure 5.
Figure 5.

Deleterious modifications of the peritoneal membrane exposed to PD. (A) Structure at the beginning of therapy. (B) Structural alterations—loss of mesothelial integrity, submesothelial fibrosis, vasculopathy, and vascular proliferation—after 5 years on PD. Brown staining indicates immunoreactivity for factor VIII, indicating the presence of blood vessels. m, mesothelium. Bar = 100 μm. (C) Summary of the time course of events and factors held responsible for driving alterations to the structure and function of the peritoneal membrane. EMT, epithelial-to-mesenchymal transition.

The cause of peritoneal fibrosis is not clear, but both human biopsy studies and animal studies suggested that uremia alone induces fibrotic changes in the peritoneum.3,71 An ongoing focus of research concerns the biocompatible nature of PD fluids and their possible fibrogenic effects. Aside from a low pH and lactate buffer, standard dialysis fluids have a high concentration of glucose and contain glucose degradation products (GDPs) as a result of heat sterilization. High concentration of glucose alone induces fibrogenic growth factors in peritoneal mesothelial cells in culture.72 Both in vivo and in vitro studies find that GDPs induce fibrosis and angiogenesis in the peritoneum. The uremic milieu, along with nonphysiologic PD solutions, leads to the appearance of advanced glycation end-products (AGEs) in the peritoneal tissues. These AGEs bind to a cognate receptor (RAGE), and this direct interaction induces fibrosis.73 The interaction between fibrosis and angiogenesis may occur at the level of inducing cytokines; TGF-β69 and inflammatory cytokines74 induce vascular endothelial growth factor and angiogenesis. Likewise, using RAGE null mice, Schwenger et al.75 demonstrated that GDPs induce both fibrosis and angiogenesis.

At the cellular level, the fibroblast is a key mediator of peritoneal fibrosis. Selective depletion of fibroblasts using a transgenic mouse with the thymidine kinase gene driven by a fibroblast-specific promoter demonstrated that selective depletion of fibroblasts decreases fibrosis and angiogenesis.76

EPS has been identified as a potential important complication of PD; however, the incidence remains controversial.77 This clinical concern has led to a need to develop realistic animal models of EPS. The standard model used to date includes a daily injection of chlorhexidine gluconate.78 We recently developed a novel model using a helper-dependent adenovirus expressing TGF-β1 (HDAdTGFβ1).79 Unlike the first-generation adenovirus, the helper-dependent adenovirus demonstrates prolonged expression. HDAdTGFβ1 administered as a single injection to the peritoneum of mice leads to a progressive fibrosis and bowel encapsulation and suppresses weight gain similar to the clinical course in EPS.

Conclusions and Perspectives

The examples outlined herein reveal how the use of transgenic mouse and cellular models has already made a significant impact on defining basic mechanisms that operate in the peritoneal membrane. The development of transgenic mice for pathways and molecules relevant to specific diseases together with the possibility of investigating minute biologic samples for numerous parameters simultaneously explains why the use of such models is set to transform research into practice. To date, studies in null mice and cells derived from these animals provide direct mechanistic insights into the transport properties of the peritoneal membrane, the role of cytokines and chemokines in regulating peritoneal inflammation, bacterial clearance and leukocyte recruitment, and pathways involved in structural and fibrogenic alterations that contribute to treatment failure (Figure 5).

As more of these models become available to target other relevant pathways and with the application of multiplex assay and DNA/RNA array technologies in these models, it will become possible to assess the interactive relationships of various physiologic and pathophysiologic pathways in the peritoneum in relation to systemic parameters. Mouse models also offer a vital preclinical resource in which the testing of various therapeutic strategies, arising from the mechanistic approaches mentioned herein, can be evaluated. Limitations of such models should be kept in mind, including the various growth and metabolic rates, the effect of the genetic background, and the possibility of adaptive mechanisms. Despite these limitations, they nevertheless offer a tremendous resources that is poised to transform peritoneal research and lead to targeted interventions to prolong PD therapy.

Disclosures

None.

Acknowledgments

O.D. is supported by the Belgian agencies Fonds National de la Recherche Scientifique and Fonds de la Recherche Scientifique Médicale, the Action de Recherches Concertées 05/10-328, an Inter-university Attraction Pole (IUAP P6/05), the DIANE network, and grants from Baxter Belgium; N.T. has been supported by the Wellcome Trust, the Medical Research Council, Arthritis Research Council, National Kidney Research Fund, the Baxter Renal Extramural Grant Program, and the Welsh Office of Research and Development; P.M. is supported by Canadian Institutes of Health Research.

We are grateful to Eric Goffin, Simon Jones, Ray Krediet, Norbert Lameire, Bengt Lindholm, Bengt Rippe, and Jean-Marc Verbavatz for support and discussions and to all our fellows and technicians for superb assistance in developing and analyzing these mouse models.

Footnotes

  • Published online ahead of print. Publication date available at www.jasn.org.

REFERENCES

  1. 1.↵
    1. Grassmann A,
    2. Gioberge S,
    3. Moeller S,
    4. Brown G
    : ESRD patients in 2004: Global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 20: 2587–2593, 2005
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Margetts PJ,
    2. Churchill DN
    : Acquired ultrafiltration dysfunction in peritoneal dialysis patients. J Am Soc Nephrol 13: 2787–2794, 2002
    OpenUrlFREE Full Text
  3. 3.↵
    1. Williams JD,
    2. Craig KJ,
    3. Topley N,
    4. Von Ruhland C,
    5. Fallon M,
    6. Newman GR,
    7. Mackenzie RK,
    8. Williams GT
    , Peritoneal Biopsy Study Group: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 13: 470–479, 2002
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Khanna R,
    2. Krediet RT
    1. Devuyst O,
    2. van Westrhenen R,
    3. Topley N
    : Long-term peritoneal dialysis patients. In: Nolph and Gokal's Textbook of Peritoneal Dialysis, 3rd Ed., edited by Khanna R, Krediet RT, New York, Springer, 2009, pp 757–780
  5. 5.↵
    1. Garosi G
    : Different aspects of peritoneal damage: Fibrosis and sclerosis. Contrib Nephrol 163: 45–53, 2009
    OpenUrlCrossRefPubMed
  6. 6.↵
    1. Augustine T,
    2. Brown PW,
    3. Davies SD,
    4. Summers AM,
    5. Wilkie ME
    : Encapsulating peritoneal sclerosis: Clinical significance and implications. Nephron Clin Pract 111: c149–c54, 2009
    OpenUrlPubMed
  7. 7.↵
    1. Carlsson O,
    2. Nielsen S,
    3. Zakaria el-R,
    4. Rippe B
    : In vivo inhibition of transcellular water channels (aquaporin-1) during acute peritoneal dialysis in rats. Am J Physiol 271: H2254–H2262, 1996
    OpenUrlPubMed
  8. 8.↵
    1. Ferrier ML,
    2. Combet S,
    3. van Landschoot M,
    4. Stoenoiu MS,
    5. Cnops Y,
    6. Lameire N,
    7. Devuyst O
    : Inhibition of nitric oxide synthase reverses changes in peritoneal permeability in a rat model of acute peritonitis. Kidney Int 60: 2343–2350, 2001
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. De Vriese AS,
    2. Tilton RG,
    3. Stephan CC,
    4. Lameire NH
    : Vascular endothelial growth factor is essential for hyperglycemia-induced structural and functional alterations of the peritoneal membrane. J Am Soc Nephrol 12: 1734–1741, 2001
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    1. Margetts PJ,
    2. Gyorffy S,
    3. Kolb M,
    4. Yu L,
    5. Hoff CM,
    6. Holmes CJ,
    7. Gauldie J
    : Antiangiogenic and antifibrotic gene therapy in a chronic infusion model of peritoneal dialysis in rats. J Am Soc Nephrol 13: 721–728, 2002
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    1. Miyata T,
    2. Devuyst O,
    3. Kurokawa K
    : Toward better dialysis compatibility: Advances in the biochemistry and pathophysiology of the peritoneal membranes. Kidney Int 61: 375–386, 2002
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Topley N
    : Animal models in peritoneal dialysis: More questions than answers? Perit Dial Int 25: 33–34, 2005
    OpenUrlFREE Full Text
  13. 13.↵
    1. Lameire N,
    2. Van Biesen W,
    3. Mortier S,
    4. De Vriese A
    : What did we learn from animal models in peritoneal dialysis? Contrib Nephrol 150: 70–76, 2006
    OpenUrlPubMed
  14. 14.↵
    1. Rao S,
    2. Verkman AS
    : Analysis of organ physiology in transgenic mice. Am J Physiol Cell Physiol 279: C1–C18, 2000
    OpenUrlPubMed
  15. 15.↵
    1. Ni J,
    2. Moulin P,
    3. Gianello P,
    4. Feron O,
    5. Balligand JL,
    6. Devuyst O
    : Mice that lack endothelial nitric oxide synthase are protected against functional and structural modifications induced by acute peritonitis. J Am Soc Nephrol 14: 3205–3216, 2003
    OpenUrlAbstract/FREE Full Text
  16. 16.↵
    1. Ni J,
    2. Cnops Y,
    3. Debaix H,
    4. Boisdé I,
    5. Verbavatz JM,
    6. Devuyst O
    : Functional and molecular characterization of a peritoneal dialysis model in the C57BL/6J mouse. Kidney Int 67: 2021–2031, 2005
    OpenUrlCrossRefPubMed
  17. 17.↵
    1. Khanna R,
    2. Krediet RT
    1. Goltoib L
    : Functional structure of the peritoneum as a dialysing membrane. In: Nolph and Gokal's Textbook of Peritoneal Dialysis, 3rd Ed., edited by Khanna R, Krediet RT, New York, Springer, 2009, pp 73–136
  18. 18.↵
    1. Brown EA,
    2. Davies SJ,
    3. Rutherford P,
    4. Meeus F,
    5. Borras M,
    6. Riegel W,
    7. Divino Filho JC,
    8. Vonesh E,
    9. van Bree M
    , EAPOS Group: Survival of functionally anuric patients on automated peritoneal dialysis: The European APD Outcome Study. J Am Soc Nephrol 14: 2948–2957, 2003
    OpenUrlAbstract/FREE Full Text
  19. 19.↵
    1. Brimble KS,
    2. Walker M,
    3. Margetts PJ,
    4. Kundhal KK,
    5. Rabbat CG
    : Meta-analysis: Peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 17: 2591–2598, 2006
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Rippe B,
    2. Stelin G,
    3. Haraldsson B
    : Computer simulations of peritoneal fluid transport in CAPD. Kidney Int 40: 315–325, 1991
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Rippe B,
    2. Venturoli D,
    3. Simonsen O,
    4. de Arteaga J
    : Fluid and electrolyte transport across the peritoneal membrane during CAPD according to the three-pore model. Perit Dial Int 24: 10–27, 2004
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    1. Agre P
    : Aquaporin water channels (Nobel Lecture). Angew Chem Int Ed Engl 43: 4278–4290, 2004
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Nielsen S,
    2. Smith BL,
    3. Christensen EI,
    4. Agre P
    : Distribution of the aquaporin CHIP in secretory and resorptive epithelia and capillary endothelia. Proc Natl Acad Sci U S A 90: 7275–7279, 1993
    OpenUrlAbstract/FREE Full Text
  24. 24.↵
    1. Devuyst O,
    2. Nielsen S,
    3. Cosyns JP,
    4. Smith BL,
    5. Agre P,
    6. Goffin E
    : Aquaporin-1 and endothelial nitric oxide synthase expression in capillary endothelia of human peritoneum. Am J Physiol 275: H234–242, 1998
    OpenUrlPubMed
  25. 25.↵
    1. Yang B,
    2. Folkesson HG,
    3. Yang J,
    4. Matthay MA,
    5. Ma T,
    6. Verkman AS
    : Reduced osmotic water permeability of the peritoneal barrier in aquaporin-1 knockout mice. Am J Physiol 276: C76–C81, 1999
    OpenUrlPubMed
  26. 26.↵
    1. Ni J,
    2. Verbavatz JM,
    3. Rippe A,
    4. Boisdé I,
    5. Moulin P,
    6. Rippe B,
    7. Verkman AS,
    8. Devuyst O
    : Aquaporin-1 plays an essential role in water permeability and ultrafiltration during peritoneal dialysis. Kidney Int 69: 1518–1525, 2006
    OpenUrlCrossRefPubMed
  27. 27.↵
    1. Stoenoiu MS,
    2. Ni J,
    3. Verkaeren C,
    4. Debaix H,
    5. Jonas J-C,
    6. Lameire N,
    7. Verbavatz J-M,
    8. Devuyst O
    : Corticosteroids induce expression of aquaporin-1 and increase transcellular water transport in rat peritoneum. J Am Soc Nephrol 14: 555–565, 2003
    OpenUrlAbstract/FREE Full Text
  28. 28.↵
    1. Krediet RT,
    2. Zuyderhoudt FM,
    3. Boeschoten EW,
    4. Arisz L
    : Alterations in the peritoneal transport of water and solutes during peritonitis in continuous ambulatory peritoneal dialysis patients. Eur J Clin Invest 17: 43–52, 1987
    OpenUrlCrossRefPubMed
  29. 29.↵
    1. Combet S,
    2. van Landschoot M,
    3. Moulin P,
    4. Piech A,
    5. Verbavatz JM,
    6. Goffin E,
    7. Balligand JL,
    8. Lameire N,
    9. Devuyst O
    : Regulation of aquaporin-1 and nitric oxide synthase isoforms in a rat model of acute peritonitis. J Am Soc Nephrol 10: 2185–2196, 1999
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Douma CE,
    2. de Waart DR,
    3. Struijk DG,
    4. Krediet RT
    : Are phospholipase A2 and nitric oxide involved in the alterations in peritoneal transport during CAPD peritonitis? J Lab Clin Med 132: 329–340, 1998
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Ni J,
    2. Cnops Y,
    3. McLoughlin RM,
    4. Topley N,
    5. Devuyst O
    : Inhibition of nitric oxide synthase reverses permeability changes in a mouse model of acute peritonitis. Perit Dial Int 25: S11–S14, 2005
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Combet S,
    2. Balligand JL,
    3. Lameire N,
    4. Goffin E,
    5. Devuyst O
    : A specific method for measurement of nitric oxide synthase enzymatic activity in peritoneal biopsies. Kidney Int 57: 332–338, 2000
    OpenUrlCrossRefPubMed
  33. 33.↵
    1. Förstermann U,
    2. Kleinert H
    : Nitric oxide synthase: Expression and expressional control of the three isoforms. Naunyn Schmiedebergs Arch Pharmacol 352: 351–364, 1995
    OpenUrlPubMed
  34. 34.↵
    1. Ni J,
    2. McLoughlin RM,
    3. Brodovitch A,
    4. Moulin P,
    5. Brouckaert P,
    6. Casadei B,
    7. Feron O,
    8. Topley N,
    9. Balligand JL,
    10. Devuyst O
    : Nitric oxide synthase isoforms play distinct roles during acute peritonitis. Nephrol Dial Transplant 25: 86–96, 2010
    OpenUrlCrossRefPubMed
  35. 35.↵
    1. Bellingan GJ,
    2. Caldwell H,
    3. Howie SE,
    4. Darnsfield I,
    5. Haslett C
    : In vivo fate of the inflammatory macrophage during the resolution of inflammation. J Immunol 157: 2577–2585, 1996
    OpenUrlAbstract
  36. 36.↵
    1. Xing Z,
    2. Gauldie J,
    3. Cox G,
    4. Baumann H,
    5. Jordana M,
    6. Lei XF,
    7. Achong MK
    : IL-6 is an anti-inflammatory cytokine required for controlling local and systemic acute inflammatory responses. J Clin Invest 101: 311–320, 1998
    OpenUrlCrossRefPubMed
  37. 37.↵
    1. Jones SA,
    2. Horiuchi S,
    3. Topley N,
    4. Yamamoto N,
    5. Fuller GM
    : The soluble interleukin-6 receptor: Mechanisms of production and implications in disease. FASEB J 15: 43–58, 2001
    OpenUrlCrossRefPubMed
  38. 38.↵
    1. Hurst SM,
    2. Wilkinson TS,
    3. McLoughlin RM,
    4. Jones S,
    5. Horiuchi S,
    6. Yamamoto N,
    7. Rose-John S,
    8. Fuller GM,
    9. Topley N,
    10. Jones SA
    : IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity 14: 705–714, 2001
    OpenUrlCrossRefPubMed
  39. 39.↵
    1. McLoughlin RM,
    2. Witowski J,
    3. Robson RL,
    4. Wilkinson TS,
    5. Hurst SM,
    6. Williams AS,
    7. Williams JD,
    8. Rose-John S,
    9. Jones SA,
    10. Topley N
    : Interplay between IFN-γ and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest 112: 598–607, 2003
    OpenUrlCrossRefPubMed
  40. 40.↵
    1. McLoughlin RM,
    2. Jenkins BJ,
    3. Grail D,
    4. Williams AS,
    5. Fielding CA,
    6. Parker CR,
    7. Ernst M,
    8. Topley N,
    9. Jones SA
    : IL-6 trans-signaling via STAT3 directs T cell infiltration in acute inflammation. Proc Natl Acad Sci U S A 102: 9589–9594, 2005
    OpenUrlAbstract/FREE Full Text
  41. 41.↵
    1. Topley N,
    2. Jörres A,
    3. Luttmann W,
    4. Petersen MM,
    5. Lang MJ,
    6. Thierauch KH,
    7. Müller C,
    8. Coles GA,
    9. Davies M,
    10. Williams JD
    : Human peritoneal mesothelial cells synthesize interleukin-6: Induction by IL-1 beta and TNF alpha. Kidney Int 43: 226–233, 1993
    OpenUrlCrossRefPubMed
  42. 42.↵
    1. Witowski J,
    2. Jörres A,
    3. Coles GA,
    4. Williams JD,
    5. Topley N
    : Superinduction of IL-6 synthesis in human peritoneal mesothelial cells is related to the induction and stabilization of IL-6 mRNA. Kidney Int 50: 1212–1223, 1996
    OpenUrlCrossRefPubMed
  43. 43.↵
    1. Nowell MA,
    2. Williams AS,
    3. Carty SA,
    4. Scheller J,
    5. Hayes AJ,
    6. Jones GW,
    7. Richards PJ,
    8. Slinn S,
    9. Ernst M,
    10. Jenkins BJ,
    11. Topley N,
    12. Rose-John S,
    13. Jones SA
    : Therapeutic targeting of IL-6 trans signaling counteracts STAT3 control of experimental inflammatory arthritis. J Immunol 182: 613–622, 2009
    OpenUrlAbstract/FREE Full Text
  44. 44.↵
    1. Kato S,
    2. Yuzawa Y,
    3. Tsuboi N,
    4. Maruyama S,
    5. Morita Y,
    6. Matsuguchi T,
    7. Matsuo S
    : Endotoxin-induced chemokine expression in murine peritoneal mesothelial cells: The role of toll-like receptor 4. J Am Soc Nephrol 15: 1289–1299, 2004
    OpenUrlAbstract/FREE Full Text
  45. 45.↵
    1. Raby AC,
    2. Le Bouder E,
    3. Colmont C,
    4. Davies J,
    5. Richards P,
    6. Coles B,
    7. George CH,
    8. Jones SA,
    9. Brennan P,
    10. Topley N,
    11. Labéta MO
    : Soluble TLR2 reduces inflammation without compromising bacterial clearance by disrupting TLR2 triggering. J Immunol 183: 506–517, 2009
    OpenUrlAbstract/FREE Full Text
  46. 46.↵
    1. Yáñez-Mó M,
    2. Lara-Pezzi E,
    3. Selgas R,
    4. Ramírez-Huesca M,
    5. Domínguez-Jiménez C,
    6. Jiménez-Heffernan JA,
    7. Aguilera A,
    8. Sánchez-Tomero JA,
    9. Bajo MA,
    10. Alvarez V,
    11. Castro MA,
    12. del Peso G,
    13. Cirujeda A,
    14. Gamallo C,
    15. Sánchez-Madrid F,
    16. López-Cabrera M
    : Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med 348: 403–413, 2003
    OpenUrlCrossRefPubMed
  47. 47.↵
    1. Margetts PJ,
    2. Bonniaud P,
    3. Liu L,
    4. Hoff CM,
    5. Holmes CJ,
    6. West-Mays JA,
    7. Kelly MM
    : Transient overexpression of TGF-beta1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol 16: 425–436, 2005
    OpenUrlAbstract/FREE Full Text
  48. 48.↵
    1. Aroeira LS,
    2. Aguilera A,
    3. Selgas R,
    4. Ramírez-Huesca M,
    5. Pérez-Lozano ML,
    6. Cirugeda A,
    7. Bajo MA,
    8. del Peso G,
    9. Sánchez-Tomero JA,
    10. Jiménez-Heffernan JA,
    11. López-Cabrera M
    : Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: Role of vascular endothelial growth factor. Am J Kidney Dis 46: 938–948, 2005
    OpenUrlCrossRefPubMed
  49. 49.↵
    1. Del Peso G,
    2. Jiménez-Heffernan JA,
    3. Bajo MA,
    4. Aroeira LS,
    5. Aguilera A,
    6. Fernández-Perpén A,
    7. Cirugeda A,
    8. Castro MJ,
    9. de Gracia R,
    10. Sánchez-Villanueva R,
    11. Sánchez-Tomero JA,
    12. López-Cabrera M,
    13. Selgas R
    : Epithelial-to-mesenchymal transition of mesothelial cells is an early event during peritoneal dialysis and is associated with high peritoneal transport. Kidney Int 108: S26–S33, 2008
    OpenUrl
  50. 50.↵
    1. Acloque H,
    2. Adams MS,
    3. Fishwick K,
    4. Bronner-Fraser M,
    5. Nieto MA
    : Epithelial-mesenchymal transitions: The importance of changing cell state in development and disease. J Clin Invest 119: 1438–1449, 2009
    OpenUrlCrossRefPubMed
  51. 51.↵
    1. Kalluri R
    : EMT: When epithelial cells decide to become mesenchymal-like cells. J Clin Invest 119: 1417–1419, 2009
    OpenUrlCrossRefPubMed
  52. 52.↵
    1. Sabbah M,
    2. Emami S,
    3. Redeuilh G,
    4. Julien S,
    5. Prévost G,
    6. Zimber A,
    7. Ouelaa R,
    8. Bracke M,
    9. De Wever O,
    10. Gespach C
    : Molecular signature and therapeutic perspective of the epithelial-to-mesenchymal transitions in epithelial cancers. Drug Resist Updat 11: 123–151, 2008
    OpenUrlCrossRefPubMed
  53. 53.↵
    1. Kalluri R,
    2. Weinberg RA
    : The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420–1428, 2009
    OpenUrlCrossRefPubMed
  54. 54.↵
    1. Yu MA,
    2. Shin KS,
    3. Kim JH,
    4. Kim YI,
    5. Chung SS,
    6. Park SH,
    7. Kim YL,
    8. Kang DH
    : HGF and BMP-7 ameliorate high glucose-induced epithelial-to-mesenchymal transition of peritoneal mesothelium. J Am Soc Nephrol 20: 567–581, 2009
    OpenUrlAbstract/FREE Full Text
  55. 55.↵
    1. Kalluri R,
    2. Neilson EG
    : Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 112: 1776–1784, 2003
    OpenUrlCrossRefPubMed
  56. 56.↵
    1. Zeisberg M,
    2. Neilson EG
    : Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 119: 1429–1437, 2009
    OpenUrlCrossRefPubMed
  57. 57.↵
    1. Cho HJ,
    2. Baek KE,
    3. Saika S,
    4. Jeong MJ,
    5. Yoo J
    : Snail is required for transforming growth factor- beta-induced epithelial-mesenchymal transition by activating PI3 kinase/Akt signal pathway. Biochem Biophys Res Commun 353: 337–343, 2007
    OpenUrlCrossRefPubMed
  58. 58.↵
    1. Bolos V,
    2. Peinado H,
    3. Perez-Moreno MA,
    4. Fraga MF,
    5. Esteller M,
    6. Cano A
    : The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: A comparison with Snail and E47 repressors. J Cell Sci 116: 499–511, 2003
    OpenUrlAbstract/FREE Full Text
  59. 59.↵
    1. Yang MH,
    2. Wu KJ
    : TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle 7: 2090–2096, 2008
    OpenUrlCrossRefPubMed
  60. 60.↵
    1. Peinado H,
    2. Olmeda D,
    3. Cano A
    : Snail, Zeb and bHLH factors in tumour progression: An alliance against the epithelial phenotype? Nat Rev Cancer 7: 415–428, 2007
    OpenUrlCrossRefPubMed
  61. 61.↵
    1. Sato M,
    2. Muragaki Y,
    3. Saika S,
    4. Roberts AB,
    5. Ooshima A
    : Targeted disruption of TGF-beta1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction. J Clin Invest 112: 1486–1494, 2003
    OpenUrlCrossRefPubMed
  62. 62.↵
    1. Banh A,
    2. Deschamps PA,
    3. Gauldie J,
    4. Overbeek PA,
    5. Sivak JG,
    6. West-Mays JA
    : Lens-specific expression of TGF-beta induces anterior subcapsular cataract formation in the absence of Smad3. Invest Ophthalmol Vis Sci 47: 3450–3460, 2006
    OpenUrlAbstract/FREE Full Text
  63. 63.↵
    1. Aguilera A,
    2. Aroeira LS,
    3. Ramirez-Huesca M,
    4. Perez-Lozano ML,
    5. Cirugeda A,
    6. Bajo MA,
    7. Del Peso G,
    8. Valenzuela-Fernandez A,
    9. Sanchez-Tomero JA,
    10. Lopez-Cabrera M,
    11. Selgas R
    : Effects of rapamycin on the epithelial-to-mesenchymal transition of human peritoneal mesothelial cells. Int J Artif Organs 28: 164–169, 2005
    OpenUrlPubMed
  64. 64.↵
    1. Hemers E,
    2. Duval C,
    3. McCaig C,
    4. Handley M,
    5. Dockray GJ,
    6. Varro A
    : Insulin-like growth factor binding protein-5 is a target of matrix metalloproteinase-7: Implications for epithelial-mesenchymal signaling. Cancer Res 65: 7363–7369, 2005
    OpenUrlAbstract/FREE Full Text
  65. 65.↵
    1. Egeblad M,
    2. Werb Z
    : New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2: 161–174, 2002
    OpenUrlCrossRefPubMed
  66. 66.↵
    1. Cheng S,
    2. Pollock AS,
    3. Mahimkar R,
    4. Olson JL,
    5. Lovett DH
    : Matrix metalloproteinase 2 and basement membrane integrity: A unifying mechanism for progressive renal injury. FASEB J 20: 1898–1900, 2006
    OpenUrlCrossRefPubMed
  67. 67.↵
    1. Ro Y,
    2. Hamada C,
    3. Inaba M,
    4. Kaneko K,
    5. Tomino Y
    : Inhibitory effects of matrix metalloproteinase inhibitor ONO-4817 on morphological alterations in chlorhexidine gluconate-induced peritoneal sclerosis rats. Nephrol Dial Transplant 22: 2838–2848, 2007
    OpenUrlCrossRefPubMed
  68. 68.↵
    1. Kawaguchi Y,
    2. Kawanishi H,
    3. Mujais S,
    4. Topley N,
    5. Oreopoulos DG
    : Encapsulating peritoneal sclerosis: Definition, etiology, diagnosis, and treatment. International Society for Peritoneal Dialysis Ad Hoc Committee on Ultrafiltration Management in Peritoneal Dialysis. Perit Dial Int 20[Suppl 4]: S43–S55, 2000
    OpenUrlAbstract/FREE Full Text
  69. 69.↵
    1. Margetts PJ,
    2. Kolb M,
    3. Galt T,
    4. Hoff CM,
    5. Shockley TR,
    6. Gauldie J
    : Gene transfer of transforming growth factor-beta1 to the rat peritoneum: Effects on membrane function. J Am Soc Nephrol 12: 2029–2039, 2001
    OpenUrlAbstract/FREE Full Text
  70. 70.↵
    1. Yoshio Y,
    2. Miyazaki M,
    3. Abe K,
    4. Nishino T,
    5. Furusu A,
    6. Mizuta Y,
    7. Harada T,
    8. Ozono Y,
    9. Koji T,
    10. Kohno S
    : TNP-470, an angiogenesis inhibitor, suppresses the progression of peritoneal fibrosis in mouse experimental model. Kidney Int 66: 1677–1685, 2004
    OpenUrlCrossRefPubMed
  71. 71.↵
    1. Combet S,
    2. Ferrier ML,
    3. Van Landschoot M,
    4. Stoenoiu M,
    5. Moulin P,
    6. Miyata T,
    7. Lameire N,
    8. Devuyst O
    : Chronic uremia induces permeability changes, increased nitric oxide synthase expression, and structural modifications in the peritoneum. J Am Soc Nephrol 12: 2146–2157, 2001
    OpenUrlAbstract/FREE Full Text
  72. 72.↵
    1. Ha H,
    2. Lee HB
    : Effect of high glucose on peritoneal mesothelial cell biology. Perit Dial Int 20[Suppl 2]: S15–S18, 2000
    OpenUrlAbstract/FREE Full Text
  73. 73.↵
    1. De Vriese AS,
    2. Flyvbjerg A,
    3. Mortier S,
    4. Tilton RG,
    5. Lameire NH
    : Inhibition of the interaction of AGE-RAGE prevents hyperglycemia-induced fibrosis of the peritoneal membrane. J Am Soc Nephrol 14: 2109–2118, 2003
    OpenUrlAbstract/FREE Full Text
  74. 74.↵
    1. Margetts PJ,
    2. Kolb M,
    3. Yu L,
    4. Hoff CM,
    5. Holmes CJ,
    6. Anthony DC,
    7. Gauldie J
    : Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol 160: 2285–2294, 2002
    OpenUrlCrossRefPubMed
  75. 75.↵
    1. Schwenger V,
    2. Morath C,
    3. Salava A,
    4. Amann K,
    5. Seregin Y,
    6. Deppisch R,
    7. Ritz E,
    8. Bierhaus A,
    9. Nawroth PP,
    10. Zeier M
    : Damage to the peritoneal membrane by glucose degradation products is mediated by the receptor for advanced glycation end-products. J Am Soc Nephrol 17: 199–207, 2006
    OpenUrlAbstract/FREE Full Text
  76. 76.↵
    1. Okada H,
    2. Inoue T,
    3. Kanno Y,
    4. Kobayashi T,
    5. Watanabe Y,
    6. Ban S,
    7. Neilson EG,
    8. Suzuki H
    : Selective depletion of fibroblasts preserves morphology and the functional integrity of peritoneum in transgenic mice with peritoneal fibrosing syndrome. Kidney Int 64: 1722–1732, 2003
    OpenUrlCrossRefPubMed
  77. 77.↵
    1. Kawanishi H,
    2. Moriishi M
    : Encapsulating peritoneal sclerosis: Prevention and treatment. Perit Dial Int 27[Suppl 2]: S289–S292, 2007
    OpenUrlAbstract/FREE Full Text
  78. 78.↵
    1. Sawada T,
    2. Ishii Y,
    3. Nakajima I,
    4. Fuchinoue S,
    5. Kubota K,
    6. Teraoka S
    : An experimental model of encapsulating peritoneal sclerosis. Perit Dial Int 29[Suppl 2]: S49–S50, 2009
    OpenUrlAbstract/FREE Full Text
  79. 79.↵
    1. Liu L,
    2. Shi CX,
    3. Ghayur A,
    4. Zhang C,
    5. Su JY,
    6. Hoff CM,
    7. Margetts PJ
    : Prolonged peritoneal gene expression using a helper-dependent adenovirus. Perit Dial Int 29: 508–516, 2009
    OpenUrlAbstract/FREE Full Text
Back to top

In this issue

View Selected Citations (0)
Print
Download PDF
Email Article
Citation Tools
Request Permissions
The Pathophysiology of the Peritoneal Membrane
Olivier Devuyst, Peter J. Margetts, Nicholas Topley
JASN Jul 2010, 21 (7) 1077-1085; DOI: 10.1681/ASN.2009070694
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo

Jump to section

More in this TOC Section

Cited By...

Similar Articles

Related Articles

  • No related articles found.